Cardiawave S.A.

Cardiawave S. A. develops innovative Non-Invasive Ultrasound Therapy (NIUT) solutions for treating calcific aortic stenosis, offering patients a surgical alternative that significantly impacts their quality of life. Founded in 2014 and headquartered in Paris, France, Cardiawave S.

A. specializes in Non-Invasive Ultrasound Therapy (NIUT) to treat calcific aortic stenosis. The company has completed eight deals, with the latest funding round occurring on September 13, 2022, when it raised EUR 2. 45 million led by UI Investissement.

CEO Olivier Pierron plays a pivotal role in leading the company's vision and strategy. Cardiawave specializes in the development of a proprietary Non-Invasive Ultrasound Therapy (NIUT) designed specifically for the treatment of calcific aortic stenosis. This innovative therapy focuses on softening the aortic valve rather than replacing it, thus offering a non-surgical alternative for patients who may not be candidates for traditional Surgical Aortic Valve Replacement (SAVR) or Transcatheter Aortic Valve Replacement (TAVR) procedures. The primary end users of this technology are elderly patients, particularly those aged 75 and above, who suffer from symptomatic severe aortic valve stenosis—a condition prevalent in developed regions including Europe and North America.

Cardiawave’s products aim to address critical unmet medical needs within these geographical markets, where an increasing number of patients are projected to seek treatment as the population ages. The company actively engages with healthcare providers and institutions to facilitate the adoption of its technology, which is supported by significant funding from initiatives such as the European Union’s Horizon 2020 program. Cardiawave generates revenue through the commercialization of its flagship product, the Valvosoft® device, which is central to its NIUT offerings. The company typically engages in direct business-to-business transactions with healthcare facilities and medical practitioners, allowing them to integrate its non-invasive therapy into their treatment protocols.

Revenue structure includes one-time purchase agreements for the Valvosoft® device along with potential service contracts for ongoing support and maintenance. Pricing plans for its devices and services are structured to meet the specific needs of healthcare providers, ensuring accessibility while maintaining care quality. This strategic approach enables Cardiawave to create a sustainable revenue model while addressing the pressing needs of patients suffering from aortic stenosis. In September 2022, Cardiawave S.

A. raised EUR 2. 45 million in venture funding from returning investors UI Investissement and participation from other individual and unspecified investors. The company plans to utilize this funding to enhance its product development efforts and expand its market presence.

Future initiatives include launching advanced iterations of their NIUT technology aimed at improving patient outcomes and targeting expansion into new markets, particularly in North America and Asia, by 2024. This approach is designed to meet the growing demand for innovative aortic stenosis treatments as the global population ages.